A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)

被引：28

作者：

Coleman, R. L. ^{[1
]}

Brady, M. F. ^{[2
]}

Herzog, T. J. ^{[3
]}

Sabbatini, P. ^{[4
]}

Armstrong, D. K. ^{[5
]}

Walker, J. L. ^{[6
]}

Kim, B. G. ^{[7
]}

Fujiwara, K. ^{[8
]}

Tewari, K. S. ^{[9
]}

O'Malley, D. M. ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] SUNY Buffalo, Buffalo, NY USA

[3] Univ Cincinnati, Cincinnati, OH USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[5] Johns Hopkins Kimmel Canc Ctr, Baltimore, MD USA

[6] Univ Oklahoma, Oklahoma City, OK USA

[7] Sungkyunkwan Univ, Sch Med, Seoul, South Korea

[8] Saitama Med Univ, Int Med Ctr, Hidaka, Japan

[9] UC Irvine, Med Ctr, Orange, CA USA

[10] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA

来源：

关键词：

D O I：

10.1016/j.ygyno.2015.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 4

页数：3